Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inhaled treprostinil in fibrotic lung disease
NL-OMON59132Phase 3Active, not recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by United Therapeutics Corporation. Started Jul 2024; status: active, not recruiting.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NL-OMON59132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59132.